Despite Drug Industry Claims, Higher List Prices Do Mean Higher Out-of-Pocket Costs for Many Patients


Despite Drug Industry Claims, Higher List Prices Do Mean Higher Out-of-Pocket Costs for Many Patients

New research suggests that as the list price of brand name drugs rise, so do out-of-pocket medical costs for these drugs—at least for some patients. This is counter to a common industry claim that patients aren’t affected by list price increases. The study found a link between list prices rising and out-of-pocket…

Read more...


Tags: Health, Science, Medicare, Martin Shkreli, Daraprim, Turing Pharmaceuticals, Pharmacy, Pharmaceutical Industry, Drug Pricing, Prescription drug, Health Sciences, U S Healthcare, Healthcare Reform In The United States, Pharmaceuticals Policy, Health Medical Pharma, Benjamin Rome, Copayment, Medication Costs, Pharmacy Benefit Management

Source:  https://gizmodo.com/despite-drug-industry-claims-higher-list-prices-do-mea-1846819278